Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Abstract

BackgroundPsoriasis can greatly impact patients’ lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin‐17A, has demonstrated good efficacy and safety in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response.ObjectiveThis analysis using the CLEAR study, a phase 3b double‐blind study comparing the efficacy and safety of secukinumab vs. ustekinumab in adults with moderate‐to‐severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships.MethodsImpact on daily activities (interference with home/shopping/garden, and influence on clothes worn) and impact on personal relationships (problems with partner/others, and sexual difficulties) as well as their corresponding subscales were selected from the Dermatology Life Quality Index scale and evaluated for patients treated with secukinumab vs. ustekinumab from the CLEAR study. Treatment differences in mean scores and proportions of responders (score = 0, indicating no impact) were evaluated through 52 weeks. Time to response was evaluated through Week 16.ResultsSignificant differences between secukinumab and ustekinumab were observed for daily activities and personal relationships at Week 16 and sustained through Week 52 (Week 52 response rates for daily activities: 82.9% vs. 73.5%, including interference with home/shopping/garden: 88.5% vs. 78.2%, and influence on clothes worn: 85.6% vs. 74.4%; personal relationships: 86.1% vs. 73.7%, including problems with partner/others: 86.6% vs. 74.8%, and sexual difficulties: 88.5% vs. 74.3%; all P < 0.01). The median time to response was 4 weeks for secukinumab vs. 8 weeks for ustekinumab for daily activities and personal relationships (both P < 0.05).ConclusionSecukinumab treatment helps patients with moderate‐to‐severe plaque psoriasis have a more normal life faster when compared to ustekinumab, by providing greater and sustained improvement in clothing choice and sexual functioning.

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

“…[15][16][17][18][19][20] The 52-week results from a phase IIIb, head-tohead, randomized, multicenter, CLEAR (NCT02074982) study demonstrated the superior efficacy of secukinumab versus ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis, with greater improvement in health-related quality of life and a comparable safety profile. [21][22][23][24] In this study, 9.2% of the total randomized subjects were of Asian origin. Despite the limited population, given that the moderate to severe form of psoriasis is less prevalent in the Asian population, a subgroup analysis from CLEAR study would be beneficial in understanding the efficacy and safety profile of secukinumab in this cohort.…”

“…Further, efficacy and safety analyses were explored up to week 52 as key secondary objectives. Both the primary and the secondary objectives have been reported separately . The focus of this subgroup analysis was to evaluate the efficacy and safety of secukinumab treatment compared with ustekinumab in Asian subjects with moderate to severe plaque psoriasis from the CLEAR study.…”

“…Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has shown long‐lasting efficacy and safety in the complete spectrum of psoriatic manifestations, including nails, scalp, palms and soles, and psoriatic arthritis . The 52‐week results from a phase IIIb, head‐to‐head, randomized, multicenter, CLEAR (NCT02074982) study demonstrated the superior efficacy of secukinumab versus ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis, with greater improvement in health‐related quality of life and a comparable safety profile . In this study, 9.2% of the total randomized subjects were of Asian origin.…”

Auswahl klinischer und diagnostischer Ergebnisse bei entzündlichen Gelenkerkrankungen

“…Unter SCK gewinnen die Patienten offenbar schneller an Lebensqualität im Vergleich zu UTK. Weitere Untersuchungen sind hier notwendig [85].…”

Beyond the headlines – JEADV editor's pick of the year 2017

“…After the era of successful use of biologics in psoriasis, kinase inhibitors are coming. The Janus‐kinase inhibitors like tofacitinib are powerful agents in modulating T‐cell responses.…”